One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer

Fan Yang, Wenwu Xiao, Yanlei Liu, Ruiwu Liu, Randall Kramer, Xiaocen Li, Yousif Ajena, Christopher M. Baehr, Tatu Rojalin, Hongyong Zhang, Kit S. Lam

Research output: Contribution to journalArticle

Abstract

Oral squamous cancers (OSC) are hallmarked by poor prognosis, delayed clinical detection, and a lack of defined, characteristic biomarkers. By screening combinatorial one-bead one-compound (OBOC) peptide libraries against oral squamous cancer cell lines, two cyclic peptide ligands, LLY12 and LLY13 were previously identified. These ligands are capable of specific binding to the oral cancer cell lines (MOK-101, HSC-3, SCC-4 and SCC-10a) but not non-cancerous keratinocytes, leukocytes, fibroblast, and endothelial cells. These two peptides were synthesized and evaluated for their binding property, cytotoxicity and cell permeability. In vitro studies indicate that both LLY12 and LLY13 were able to bind to oral cancer cells with high specificity but did not show any cytotoxicity against human keratinocytes. Biotinylated LLY13, in complex with streptavidin-alexa488 was taken up by live oral cancer cells, thus rendering it as an excellent candidate vehicle for efficient delivery of drug loaded-nanoparticles. In vivo and ex vivo near infra-red fluorescence imaging studies confirmed the in vivo targeting efficiency and specificity of LLY13 in oral cancer orthotopic murine xenograft model. In vivo studies also showed that LLY13 was able to accumulate in the OSC tumors and demarcate the tumor margins in orthotopic xenograft model. Together, our data supports LLY13 as a promising theranostic agent against OSC.

Original languageEnglish (US)
Pages (from-to)5468-5479
Number of pages12
JournalOncotarget
Volume10
Issue number52
StatePublished - Jan 1 2019

Fingerprint

Mouth Neoplasms
Ligands
Therapeutics
Keratinocytes
Heterografts
Peptide Library
Cell Line
Cyclic Peptides
Streptavidin
Optical Imaging
Nanoparticles
Permeability
Neoplasms
Leukocytes
Endothelial Cells
Fibroblasts
Biomarkers
Epithelial Cells
Peptides
Pharmaceutical Preparations

Keywords

  • Cancer-targeting peptide
  • Optical imaging
  • Oral squamous cancer
  • Orthotopic xenograft model
  • α3 integrin

ASJC Scopus subject areas

  • Oncology

Cite this

One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer. / Yang, Fan; Xiao, Wenwu; Liu, Yanlei; Liu, Ruiwu; Kramer, Randall; Li, Xiaocen; Ajena, Yousif; Baehr, Christopher M.; Rojalin, Tatu; Zhang, Hongyong; Lam, Kit S.

In: Oncotarget, Vol. 10, No. 52, 01.01.2019, p. 5468-5479.

Research output: Contribution to journalArticle

Yang, F, Xiao, W, Liu, Y, Liu, R, Kramer, R, Li, X, Ajena, Y, Baehr, CM, Rojalin, T, Zhang, H & Lam, KS 2019, 'One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer', Oncotarget, vol. 10, no. 52, pp. 5468-5479.
Yang, Fan ; Xiao, Wenwu ; Liu, Yanlei ; Liu, Ruiwu ; Kramer, Randall ; Li, Xiaocen ; Ajena, Yousif ; Baehr, Christopher M. ; Rojalin, Tatu ; Zhang, Hongyong ; Lam, Kit S. / One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer. In: Oncotarget. 2019 ; Vol. 10, No. 52. pp. 5468-5479.
@article{29a7f9384f5c4d4490931677a0e2bce8,
title = "One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer",
abstract = "Oral squamous cancers (OSC) are hallmarked by poor prognosis, delayed clinical detection, and a lack of defined, characteristic biomarkers. By screening combinatorial one-bead one-compound (OBOC) peptide libraries against oral squamous cancer cell lines, two cyclic peptide ligands, LLY12 and LLY13 were previously identified. These ligands are capable of specific binding to the oral cancer cell lines (MOK-101, HSC-3, SCC-4 and SCC-10a) but not non-cancerous keratinocytes, leukocytes, fibroblast, and endothelial cells. These two peptides were synthesized and evaluated for their binding property, cytotoxicity and cell permeability. In vitro studies indicate that both LLY12 and LLY13 were able to bind to oral cancer cells with high specificity but did not show any cytotoxicity against human keratinocytes. Biotinylated LLY13, in complex with streptavidin-alexa488 was taken up by live oral cancer cells, thus rendering it as an excellent candidate vehicle for efficient delivery of drug loaded-nanoparticles. In vivo and ex vivo near infra-red fluorescence imaging studies confirmed the in vivo targeting efficiency and specificity of LLY13 in oral cancer orthotopic murine xenograft model. In vivo studies also showed that LLY13 was able to accumulate in the OSC tumors and demarcate the tumor margins in orthotopic xenograft model. Together, our data supports LLY13 as a promising theranostic agent against OSC.",
keywords = "Cancer-targeting peptide, Optical imaging, Oral squamous cancer, Orthotopic xenograft model, α3 integrin",
author = "Fan Yang and Wenwu Xiao and Yanlei Liu and Ruiwu Liu and Randall Kramer and Xiaocen Li and Yousif Ajena and Baehr, {Christopher M.} and Tatu Rojalin and Hongyong Zhang and Lam, {Kit S.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "10",
pages = "5468--5479",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "52",

}

TY - JOUR

T1 - One-bead one-compound combinatorial library derived targeting ligands for detection and treatment of oral squamous cancer

AU - Yang, Fan

AU - Xiao, Wenwu

AU - Liu, Yanlei

AU - Liu, Ruiwu

AU - Kramer, Randall

AU - Li, Xiaocen

AU - Ajena, Yousif

AU - Baehr, Christopher M.

AU - Rojalin, Tatu

AU - Zhang, Hongyong

AU - Lam, Kit S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Oral squamous cancers (OSC) are hallmarked by poor prognosis, delayed clinical detection, and a lack of defined, characteristic biomarkers. By screening combinatorial one-bead one-compound (OBOC) peptide libraries against oral squamous cancer cell lines, two cyclic peptide ligands, LLY12 and LLY13 were previously identified. These ligands are capable of specific binding to the oral cancer cell lines (MOK-101, HSC-3, SCC-4 and SCC-10a) but not non-cancerous keratinocytes, leukocytes, fibroblast, and endothelial cells. These two peptides were synthesized and evaluated for their binding property, cytotoxicity and cell permeability. In vitro studies indicate that both LLY12 and LLY13 were able to bind to oral cancer cells with high specificity but did not show any cytotoxicity against human keratinocytes. Biotinylated LLY13, in complex with streptavidin-alexa488 was taken up by live oral cancer cells, thus rendering it as an excellent candidate vehicle for efficient delivery of drug loaded-nanoparticles. In vivo and ex vivo near infra-red fluorescence imaging studies confirmed the in vivo targeting efficiency and specificity of LLY13 in oral cancer orthotopic murine xenograft model. In vivo studies also showed that LLY13 was able to accumulate in the OSC tumors and demarcate the tumor margins in orthotopic xenograft model. Together, our data supports LLY13 as a promising theranostic agent against OSC.

AB - Oral squamous cancers (OSC) are hallmarked by poor prognosis, delayed clinical detection, and a lack of defined, characteristic biomarkers. By screening combinatorial one-bead one-compound (OBOC) peptide libraries against oral squamous cancer cell lines, two cyclic peptide ligands, LLY12 and LLY13 were previously identified. These ligands are capable of specific binding to the oral cancer cell lines (MOK-101, HSC-3, SCC-4 and SCC-10a) but not non-cancerous keratinocytes, leukocytes, fibroblast, and endothelial cells. These two peptides were synthesized and evaluated for their binding property, cytotoxicity and cell permeability. In vitro studies indicate that both LLY12 and LLY13 were able to bind to oral cancer cells with high specificity but did not show any cytotoxicity against human keratinocytes. Biotinylated LLY13, in complex with streptavidin-alexa488 was taken up by live oral cancer cells, thus rendering it as an excellent candidate vehicle for efficient delivery of drug loaded-nanoparticles. In vivo and ex vivo near infra-red fluorescence imaging studies confirmed the in vivo targeting efficiency and specificity of LLY13 in oral cancer orthotopic murine xenograft model. In vivo studies also showed that LLY13 was able to accumulate in the OSC tumors and demarcate the tumor margins in orthotopic xenograft model. Together, our data supports LLY13 as a promising theranostic agent against OSC.

KW - Cancer-targeting peptide

KW - Optical imaging

KW - Oral squamous cancer

KW - Orthotopic xenograft model

KW - α3 integrin

UR - http://www.scopus.com/inward/record.url?scp=85072692545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072692545&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85072692545

VL - 10

SP - 5468

EP - 5479

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 52

ER -